These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 28647608)

  • 21. Discovery of cancer common and specific driver gene sets.
    Zhang J; Zhang S
    Nucleic Acids Res; 2017 Jun; 45(10):e86. PubMed ID: 28168295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling.
    Azad AK; Lawen A; Keith JM
    BMC Syst Biol; 2015 Jan; 9():2. PubMed ID: 25599599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes.
    Chen J; Xu J; Li Y; Zhang J; Chen H; Lu J; Wang Z; Zhao X; Xu K; Li Y; Li X; Zhang Y
    Oncotarget; 2017 Feb; 8(6):10171-10184. PubMed ID: 28052038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A canonical correlation analysis-based dynamic bayesian network prior to infer gene regulatory networks from multiple types of biological data.
    Baur B; Bozdag S
    J Comput Biol; 2015 Apr; 22(4):289-99. PubMed ID: 25844668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Semiparametric Bayesian kernel survival model for evaluating pathway effects.
    Zhang L; Kim I
    Stat Methods Med Res; 2019; 28(10-11):3301-3317. PubMed ID: 30289021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Local network component analysis for quantifying transcription factor activities.
    Shi Q; Zhang C; Guo W; Zeng T; Lu L; Jiang Z; Wang Z; Liu J; Chen L
    Methods; 2017 Jul; 124():25-35. PubMed ID: 28710010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
    Hachim IY; Shams A; Lebrun JJ; Ali S
    Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis.
    Jhan JR; Andrechek ER
    Oncogene; 2017 Jun; 36(25):3553-3561. PubMed ID: 28135251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BGRMI: A method for inferring gene regulatory networks from time-course gene expression data and its application in breast cancer research.
    Iglesias-Martinez LF; Kolch W; Santra T
    Sci Rep; 2016 Nov; 6():37140. PubMed ID: 27876826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Learning the local Bayesian network structure around the ZNF217 oncogene in breast tumours.
    Prestat E; de Morais SR; Vendrell JA; Thollet A; Gautier C; Cohen PA; Aussem A
    Comput Biol Med; 2013 May; 43(4):334-41. PubMed ID: 23375235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathway level analysis by augmenting activities of transcription factor target genes.
    Jung H; Lee E; Kim JW; Lee D
    IET Syst Biol; 2009 Nov; 3(6):534-42. PubMed ID: 19947779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of outcome-related driver mutations in cancer using conditional co-occurrence distributions.
    Treviño V; Martínez-Ledesma E; Tamez-Peña J
    Sci Rep; 2017 Feb; 7():43350. PubMed ID: 28240231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bayesian nonlinear model selection for gene regulatory networks.
    Ni Y; Stingo FC; Baladandayuthapani V
    Biometrics; 2015 Sep; 71(3):585-95. PubMed ID: 25854759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of upstream transcription factors (TFs) for expression signature genes in breast cancer.
    Zang H; Li N; Pan Y; Hao J
    Gynecol Endocrinol; 2017 Mar; 33(3):193-198. PubMed ID: 27809618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Network-Based Method for Inferring Cancer Progression at the Pathway Level from Cross-Sectional Mutation Data.
    Wu H; Gao L; Kasabov NK
    IEEE/ACM Trans Comput Biol Bioinform; 2016; 13(6):1036-1044. PubMed ID: 26915128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction of a gene-gene interaction network with a combined score across multiple approaches.
    Zhang AM; Song H; Shen YH; Liu Y
    Genet Mol Res; 2015 Jun; 14(2):7018-30. PubMed ID: 26125911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening of the prognostic targets for breast cancer based co-expression modules analysis.
    Liu H; Ye H
    Mol Med Rep; 2017 Oct; 16(4):4038-4044. PubMed ID: 28731166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highly informative marker sets consisting of genes with low individual degree of differential expression.
    Galatenko VV; Shkurnikov MY; Samatov TR; Galatenko AV; Mityakina IA; Kaprin AD; Schumacher U; Tonevitsky AG
    Sci Rep; 2015 Oct; 5():14967. PubMed ID: 26446398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ESEA: Discovering the Dysregulated Pathways based on Edge Set Enrichment Analysis.
    Han J; Shi X; Zhang Y; Xu Y; Jiang Y; Zhang C; Feng L; Yang H; Shang D; Sun Z; Su F; Li C; Li X
    Sci Rep; 2015 Aug; 5():13044. PubMed ID: 26267116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.